(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 8.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Sangamo Therapeutics's revenue in 2025 is $81,706,000.On average, 2 Wall Street analysts forecast SGMO's revenue for 2025 to be $19,686,543,896, with the lowest SGMO revenue forecast at $6,275,557,288, and the highest SGMO revenue forecast at $33,097,530,505. On average, 2 Wall Street analysts forecast SGMO's revenue for 2026 to be $14,889,363,085, with the lowest SGMO revenue forecast at $2,986,923,902, and the highest SGMO revenue forecast at $26,791,802,268.
In 2027, SGMO is forecast to generate $35,360,351,642 in revenue, with the lowest revenue forecast at $21,361,031,538 and the highest revenue forecast at $49,359,671,746.